Core Viewpoint - Federal Pharmaceutical (03933) has shown significant stock performance, rising over 4% following the successful presentation of its diabetes treatment products at a recent conference, indicating strong market interest and potential growth in the GLP-1 treatment sector [1] Group 1: Product Development - The company showcased its diabetes product lineup, including the recently launched liraglutide injection "Federal Yuli Tai" and the upcoming semaglutide injection "Federal Youmei Tai," marking important advancements in the GLP-1 target treatment area [1] - The collaboration between Federal Pharmaceutical's subsidiary, Federal Bio, and Novo Nordisk for the exclusive licensing of UBT251 highlights the global market potential of this product and aims to accelerate its development process [1] Group 2: Strategic Partnerships - The partnership with Novo Nordisk not only validates the global market value of UBT251 but also leverages Novo Nordisk's resources to enhance the product's development [1] - This collaboration represents a significant achievement in Federal Pharmaceutical's innovation transformation, aligning its GLP-1 innovative drugs with international standards and expanding its reach to nearly 80 countries and regions [1]

Group 1 - The core viewpoint is that the Hong Kong innovative drug concept stocks are experiencing a continuous decline, with Federal Pharmaceutical dropping over 8% [1] - Other companies such as Crystal Technology Holdings, Giant Biologics, Sanofi Pharmaceutical, and China Biopharmaceutical are also following the downward trend [1]

Core Points - The company, 联邦制药 (03933), announced the issuance of 3.3698 million shares as part of its 2023 share award plan, contingent upon the achievement of performance targets for 2024 [1] Group 1 - The total number of shares awarded is 3.3698 million [1] - The shares will be allocated to relevant recipients on November 13, 2025 [1] - The allocation is based on the terms of the 2023 share award plan [1]

Core Viewpoint - The company, 联邦制药, announced the issuance of 3.3698 million shares as part of its 2023 share award plan, contingent upon the achievement of performance targets for 2024, with the shares set to vest on November 13, 2025 [1] Summary by Category - **Share Issuance**: A total of 3.3698 million shares will be awarded under the 2023 share award plan [1] - **Performance Conditions**: The vesting of these shares is dependent on the achievement of specific performance targets for the year 2024 [1] - **Vesting Date**: The shares are scheduled to vest on November 13, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島成立之有限公司 ) (股份代號: 3933) 於本公告日期，董事會成員包括：執行董事蔡海山先生、梁永康先生、蔡紹哲女士、方 煜平先生、鄒鮮紅女士及朱蘇燕女士；以及獨立非執行董事張品文先生、宋敏教授及傅 秋實博士。 自願公告 獎勵股份的歸屬 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 茲提述本公司日期為二零二三年十一月十三日的公告（「該公告」），內容有關根據二零 二三年股份獎勵計劃的條款向承授人授出合共12,096,900股獎勵股份。除文義另有界定外， 本公告所用詞彙與該公告所賦予者具有相同涵義。 董事會公佈，共3,369,800股獎勵股份已根據二零二三年股份獎勵計劃的條款及二零二四 年績效目標的達標情況，於二零二五年十一月十三日歸屬於相關的 ...

Group 1 - The stock of Hong Kong-listed company 联邦制药 (03933.HK) experienced a nearly 3% increase in early trading, with a current rise of 2.32% to HKD 12.8 [2] - The trading volume reached HKD 64.0646 million [2]

Group 1 - The core point of the article is that Federal Pharmaceutical (03933) has seen a nearly 3% increase in its stock price following the announcement of successful Phase II clinical trials for its innovative drug TUL01101 for moderate to severe atopic dermatitis in adults [1] - The company reported that TUL01101 met its expected goals in the Phase II clinical study, which supports its progression to the next phase of clinical research [1] - Federal Pharmaceutical has completed communication with regulatory authorities regarding TUL01101's End of Phase 2 (EOP2) and is initiating Phase III clinical trials in China for moderate to severe atopic dermatitis patients [1]

Core Viewpoint - Federal Pharmaceutical (03933) has seen a nearly 3% increase in early trading, currently up 2.32% at HKD 12.8, with a trading volume of HKD 64.0646 million [1] Group 1: Clinical Research Progress - The company announced that its self-developed innovative drug TUL01101 has completed Phase II clinical trials in adult patients with moderate to severe atopic dermatitis in China [1] - TUL01101 met the expected goals in the Phase II clinical study, supporting its progression to the next stage of clinical research [1] - The company has completed communication with regulatory authorities regarding TUL01101's EOP2 and is initiating Phase III clinical trials in China for moderate to severe atopic dermatitis patients [1]

Core Viewpoint - The company has successfully completed Phase II clinical trials for its innovative drug TUL01101 for moderate to severe atopic dermatitis in adults, demonstrating significant efficacy and safety [1][2] Group 1: Clinical Trial Details - The Phase II study was a multicenter, randomized, double-blind, parallel, placebo-controlled trial involving 201 participants [1] - Participants were randomly assigned to three different dosage groups (20mg, 40mg, 60mg) and a placebo group, with daily administration for 12 weeks [1] - The primary efficacy endpoint was the change in the Eczema Area and Severity Index (EASI) score from baseline at week 12, with key secondary endpoints including the proportion of participants achieving EASI75 response and the Investigator's Global Assessment (IGA) response [1] Group 2: Efficacy Results - Results showed significant efficacy across all dosage groups, with EASI scores decreasing notably from week 1 [2] - At week 12, the EASI score changes from baseline were -81.98% for the 20mg group, -79.87% for the 40mg group, and -87.85% for the 60mg group [2] - EASI75 response rates were 78.0%, 80.0%, and 84.0% for the respective dosage groups, while IGA response rates were 46.0%, 52.0%, and 68.0% [2] Group 3: Safety and Next Steps - The overall safety and tolerability of TUL01101 were good, with the most common adverse event being upper respiratory infection, mostly mild to moderate in severity [2] - No new safety signals were reported beyond those associated with similar products [2] - The successful completion of Phase II trials supports the initiation of Phase III clinical trials, which are currently being launched in China for moderate to severe atopic dermatitis [2]

Core Viewpoint - The company has successfully completed Phase II clinical trials for its innovative drug TUL01101, demonstrating significant efficacy and safety in treating moderate to severe atopic dermatitis in adults [1][2]. Group 1: Clinical Trial Details - The Phase II clinical study was a multicenter, randomized, double-blind, parallel, placebo-controlled trial involving 201 adult participants with moderate to severe atopic dermatitis [1]. - Participants were randomly assigned to three different dosage groups (20mg, 40mg, 60mg) and a placebo group, with treatment administered once daily for 12 weeks [1]. - The primary efficacy endpoint was the change in the Eczema Area and Severity Index (EASI) score from baseline at week 12, with key secondary endpoints including the proportion of participants achieving EASI75 response and Investigator's Global Assessment (IGA) response [1]. Group 2: Trial Results - Results indicated that TUL01101 significantly improved EASI scores, with reductions of -81.98%, -79.87%, and -87.85% for the 20mg, 40mg, and 60mg groups, respectively, compared to baseline [2]. - EASI75 response rates were 78.0%, 80.0%, and 84.0% for the respective dosage groups, while IGA response rates were 46.0%, 52.0%, and 68.0% [2]. - The overall safety profile of TUL01101 was favorable, with the most common adverse event being upper respiratory tract infection, primarily mild to moderate in severity [2]. Group 3: Future Development - TUL01101 is a highly selective JAK1 inhibitor, currently approved for clinical trials in atopic dermatitis and rheumatoid arthritis in China [3]. - The company plans to continue expanding clinical research for TUL01101 in the field of autoimmune diseases [3].